Scale-up of malaria prevention could save 3.5M lives, says report
3.5 million lives could be saved over the next five years through the rapid scale-up of malaria prevention and treatment measures in the 30 hardest hit countries in Africa, says a new report released at the World Economic Forum in Davos, Switzerland.
Rapid scale-up would increase annual economic output by as much as $30.0 billion in Africa, prevent 672 million malaria cases and free up 427,000 needed hospital beds over five years, according to the paper, entitled We Can't Afford to Wait: The Business Case for Rapid Scale-up of Malaria Control in Africa, which was prepared by Malaria No More and McKinsey & Company on behalf of the Roll Back Malaria Partnership (RBMP).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze